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Background:  Endothelin receptor antagonists are regarded a cornerstone in treatment of pulmonary arterial hypertension associated 
with congenital heart disease (PAH-CHD). Currently macitentan, a potential successor of the widely applied bosentan, is being introduced. 
A recent trial has proven its outstanding effects on exercise capacity and mortality, compared to placebo. However a direct clinical 
comparison with bosentan is lacking. Using our large longitudinal cohort of PAH-CHD patients, we aim to provide insight in potential 
benefits of switching bosentan to macitentan.
methods:  In this multicenter prospective cohort study, all adult PAH-CHD patients on bosentan are scheduled to switch to macitentan 
with continuation of study protocol measurements. These include laboratory tests, 6-minute walk tests (6-MWT), cardiopulmonary exercise 
tests, echocardiography, MRI and quality of life questionnaires at regular intervals during follow-up. All measurements will be compared 
with previously collected prospective data during bosentan treatment using paired samples t-tests.
results:  From 2006 a total of 84 PAH-CHD patients started bosentan, of whom 44 patients are currently still alive (mean age 46±14 years, 
follow-up 6.2±2.6 years, 46% male, 36% Down syndrome). Currently 25 patients were switched to macitentan. No serious adverse events 
were reported. Three months macitentan treatment resulted in improved 6-MWT (429±110 to 438±122 meters, mean values) and resting 
saturation (83 to 86%, median values) although non-significant. However macitentan reduced NT-pro-BNP (1143 to 804 ng/L, median 
values, p=0.05) and high sensitive Troponin-T (0.016 to 0.010 µg/L, median values, p=0.01). These and additional results after treatment 
switch will be presented.
Conclusion:  This is the first study to provide important clinical and safety information on the effect of switching bosentan to macitentan in 
adult PAH-CHD patients. After three months of macitentan treatment in the first 25 patients significant declines in cardiac markers NT-pro-
BNP and Troponin-T are already apparent.
